SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on November 21, 2019. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM. The filing reports a material event occurring on the date of the report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial results.
Material Changes and Events
- Item 8.01 (Entry Into a Material Definitive Agreement): The Company announced the commencement of its first clinical trial for its PURE EPTM System.
- Item 9.01 (Financial Statements and Exhibits): A press release dated November 21, 2019, detailing the clinical trial commencement is filed as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the context of the clinical trial announcement. The document serves primarily to disclose the initiation of the clinical trial as a material event.
Investor Verification Checklist
- Verify the specific objectives and design of the PURE EPTM System clinical trial referenced in Exhibit 99.1.
- Confirm the current regulatory status of the PURE EPTM System with the FDA.
- Review the Company's most recent 10-K or 10-Q filings for up-to-date financial position and liquidity metrics, as this 8-K does not contain them.
- Monitor subsequent filings for updates on the clinical trial progress and any potential impact on the Company's capital requirements.